Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health's subsidiary Optival Health faces drug license suspensions for 5-8 days across four stores in multiple states. The expected financial impact is ₹0.17 Crore.

Key figures
Value₹0.17 Cr
Source

BSE filing, NSE: MEDPLUS. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Medplus Health Services Ltd: key numbers

Share price
₹610.60
Market cap
₹7,336 Cr
Revenue (annual)
₹6,892 Cr
Net profit (annual)
₹219.7 Cr
P/E (TTM)
34.8×Sector 51.1×
Promoter holding
40.19%+0.00% QoQ
FII holding
12.58%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Medplus Health Services Ltd

All →

Other adverse business impact announcements

All →